University of Notre Dame DU Lac Increases Position in Insmed, Inc. (INSM)

University of Notre Dame DU Lac boosted its position in Insmed, Inc. (NASDAQ:INSM) by 43.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 202,413 shares of the biopharmaceutical company’s stock after acquiring an additional 61,652 shares during the period. Insmed accounts for approximately 1.8% of University of Notre Dame DU Lac’s portfolio, making the stock its 11th largest holding. University of Notre Dame DU Lac owned approximately 0.26% of Insmed worth $6,317,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in INSM. Schwab Charles Investment Management Inc. grew its holdings in Insmed by 6.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 283,167 shares of the biopharmaceutical company’s stock valued at $4,959,000 after buying an additional 18,331 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Insmed by 191.4% during the first quarter. Bank of America Corp DE now owns 33,804 shares of the biopharmaceutical company’s stock worth $592,000 after purchasing an additional 22,204 shares in the last quarter. State Street Corp grew its holdings in shares of Insmed by 4.8% during the first quarter. State Street Corp now owns 1,499,611 shares of the biopharmaceutical company’s stock worth $26,259,000 after purchasing an additional 68,319 shares in the last quarter. Credit Suisse AG grew its holdings in shares of Insmed by 12.6% during the first quarter. Credit Suisse AG now owns 72,399 shares of the biopharmaceutical company’s stock worth $1,268,000 after purchasing an additional 8,089 shares in the last quarter. Finally, Pictet Asset Management Ltd. grew its holdings in shares of Insmed by 5.3% during the second quarter. Pictet Asset Management Ltd. now owns 131,143 shares of the biopharmaceutical company’s stock worth $2,022,000 after purchasing an additional 6,600 shares in the last quarter. Institutional investors and hedge funds own 95.29% of the company’s stock.

Shares of Insmed, Inc. (INSM) opened at $28.49 on Tuesday. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. Insmed, Inc. has a 12-month low of $11.49 and a 12-month high of $32.94.

In other Insmed news, Director Donald J. Hayden, Jr. sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total value of $487,500.00. Following the completion of the sale, the director now owns 71,131 shares in the company, valued at $2,311,757.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Melvin Md Sharoky sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total value of $1,368,500.00. The disclosure for this sale can be found here. Insiders sold 110,000 shares of company stock valued at $3,191,150 in the last quarter. Corporate insiders own 5.10% of the company’s stock.

INSM has been the subject of several recent analyst reports. Leerink Swann boosted their price objective on Insmed from $27.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, September 5th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Insmed in a report on Monday, November 6th. Cowen reissued a “buy” rating and set a $54.00 price objective on shares of Insmed in a report on Friday, November 3rd. Zacks Investment Research lowered Insmed from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $34.50.

ILLEGAL ACTIVITY NOTICE: This article was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/12/05/university-of-notre-dame-du-lac-increases-position-in-insmed-inc-insm.html.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply